Literature DB >> 2400997

Antiproliferative and cytotoxic effects of single and combined treatment with tumor necrosis factor alpha and/or alpha interferon on a human renal cell carcinoma xenotransplanted into nu/nu mice: cell kinetic studies.

H Baisch1, U Otto, G Klöppel.   

Abstract

A human renal cell carcinoma serially transplanted into nude mice was treated with recombinant human tumor necrosis factor alpha (TNF-alpha), recombinant human alpha interferon (IFN-alpha), and a combination of both. All treatments resulted in a significantly reduced tumor growth. The greatest effect was obtained with the combination of TNF-alpha and IFN-alpha. This latter treatment completely eradicated tumors which were smaller than 50 mm3 at the beginning of treatment. Cell kinetic analysis using the bromodeoxyuridine technique and flow cytometry revealed a prolongation of the transition time through S-phase from 7.9 h in the case of control tumors to 10.5 h for tumors treated with IFN-alpha and TNF-alpha. Single treatment with either TNF-alpha or IFN-alpha had only minor effects. The bromodeoxyuridine labeling index was unaffected by IFN-alpha (16.6%; control, 15.2%) but was reduced to 12.1 and 11.7% when tumors were treated with TNF-alpha and IFN-alpha plus TNF-alpha, respectively. The calculated potential doubling times were 2.3 and 2.8 days, respectively, for tumors treated with TNF-alpha or IFN-alpha plus TNF-alpha. When treated with IFN-alpha, the potential doubling time (1.7 days) was similar to that of the control (1.6 days), indicating that the main effect of TNF-alpha was antiproliferative. Conversely, the calculated cell loss factors increased after IFN-alpha and combined treatment but not after TNF-alpha treatment. Combined treatment augmented cytotoxicity, but the cell kinetic characteristics of surviving cells remained similar to those of tumors treated with TNF-alpha alone. Histological analysis showed a distinctly reduced mitotic activity but no coagulative necroses after treatment with TNF-alpha. IFN-alpha and, in particular, IFN-alpha plus TNF-alpha induced cytoplasmic vacuolization, nuclear pyknosis, and cell death, which resulted in tumor regression. These data suggest that, in this particular tumor model, TNF-alpha produces mainly antiproliferative effects, whereas IFN-alpha acts via cytotoxic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2400997

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  p53-independent apoptosis induced by paclitaxel through an indirect mechanism.

Authors:  J S Lanni; S W Lowe; E J Licitra; J O Liu; T Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.

Authors:  Z Gazit; D W Weiss; D Shouval; M Yechezkeli; V Schirrmacher; M Notter; J Walter; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor.

Authors:  X Zhao; G J van Steenbrugge; F H Schröder
Journal:  Urol Res       Date:  1992

4.  Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.

Authors:  Mehmet Asim Bilen; Amado J Zurita; Nasreen A Ilias-Khan; Hsiang-Chun Chen; Xuemei Wang; Alper Y Kearney; Sherie Hodges; Eric Jonasch; Shixia Huang; Aarif Yusuf Khakoo; Nizar M Tannir
Journal:  Oncologist       Date:  2015-08-25

Review 5.  Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma.

Authors:  M M Walther; S B Jennings; P L Choyke; M Andrich; K Hurley; W M Linehan; S A Rosenberg; R B Alexander
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

6.  Cytotoxic effect of diphtheria toxin used alone or in combination with other agents on human renal cell carcinoma cell lines.

Authors:  Y Mizutani; B Bonavida; O Yoshida
Journal:  Urol Res       Date:  1994
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.